Inogen expects to exceed full-year guidance 

GOLETA, Calif. – Inogen estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting YOY growth of 6% and exceeding the company’s previous full-year guidance of $329 million to $331 million. 

The company says its performance was driven by strong, double-digit growth in business-to-business revenue, while it continues to work to stabilize direct-to-consumer revenue with initiatives to enhance overall profitability. 

“2024 was a very successful year for Inogen,” said Kevin Smith, president and CEO of Inogen. “We drove a return to revenue growth, improved profitability and disciplined cost management. Achievements in the (fourth) quarter included the launch of Rove 4 and FDA clearance for our SIMEOX 200 device, which diversifies our global product offerings, all while continuing to extend our reach and aiming to improve outcomes for patients. I am confident in our team’s ability to continue delivering on our commitments and providing leading devices for patients with respiratory diseases in 2025 and beyond.” 

Inogen estimates preliminary, unaudited revenue in the fourth quarter of 2024 to be in the range of $79 million to $80 million, reflecting year-over-year growth of 4% to 5%.  

• Related: Inogen has received 510(k) clearance from the U.S. Food and Drug Administration for the Simeox 200 Airway Clearance Device, expanding the company’s ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. 
• Related: Inogen has launched its Inogen Rove 4 Portable Oxygen Concentrator, a lightweight, user-friendly device with an additional fourth flow setting delivering up to 840ml/min of oxygen.